↓ Skip to main content

Outcome of patients on second line antiretroviral therapy under programmatic condition in India

Overview of attention for article published in BMC Infectious Diseases, November 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Outcome of patients on second line antiretroviral therapy under programmatic condition in India
Published in
BMC Infectious Diseases, November 2015
DOI 10.1186/s12879-015-1270-8
Pubmed ID
Authors

Jaya Chakravarty, Shyam Sundar, Ankita Chourasia, Pallav Narayan Singh, Swarali Kurle, Srikanth P. Tripathy, Devidas N Chaturbhuj, Madhukar Rai, Amit Kumar Agarwal, Rabindra Nath Mishra, Ramesh S. Paranjape

Abstract

The National AIDS Control Organization of India has been providing free second line antiretroviral therapy (ART) since 2008. This observational study reports the survival and virologic suppression of patients on second-line ART under programmatic condition and type of mutations acquired by those failing therapy. 170 patients initiated on second-line therapy between 2008 and 2012 were followed up till 2013. Viral Load (VL) was repeated at 6 months for all patients and at 12 months for those with VL >400 copies/ml at 6 months. Adequate virological response was defined as plasma HIV-1 VL <400 copies/ml and virological failure was defined as VL >1000 copies/ml. Genotyping was done in 16 patients with virological failure. Out of 170 patients, 110 (64.7 %) were alive and on therapy and 35 (20.5 %) expired. In the first year the occurrence of death was 13.7 /100 person years while between1 and 5 year it was 3.88 /100 person years. In the first year, duration of immunological failure >12 months, weight <45 kg, WHO clinical stage 3 and 4 and WHO criteria CD4 count less than pretherapy baseline [hazard ratio HR 4.2. 15.8, 11.9 & 4.1 respectively] and beyond first year poor first and second line adherence and first line CD4 count < 200/μL [HR 5.2,15.8, 3.3 respectively] had high risk of death. 119/152 (78.2 %) had adequate virological response and 27/152 (17.7 %) had virological failure. High viral load at baseline and poor second line adherence (Odds Ratio 3.4 & 2.8 respectively) had increased risk of virological failure. Among those genotyped, 50 % had major Protease Inhibitor mutation (M46I commonest) however 87.5 % were still susceptible to darunavir. Second line therapy has shown high early mortality but good virological suppression under programmatic conditions.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 <1%
Unknown 106 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 24 22%
Researcher 14 13%
Student > Ph. D. Student 14 13%
Student > Postgraduate 10 9%
Other 9 8%
Other 15 14%
Unknown 21 20%
Readers by discipline Count As %
Medicine and Dentistry 43 40%
Nursing and Health Professions 12 11%
Immunology and Microbiology 8 7%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Agricultural and Biological Sciences 4 4%
Other 6 6%
Unknown 27 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2016.
All research outputs
#20,334,427
of 22,879,161 outputs
Outputs from BMC Infectious Diseases
#6,480
of 7,691 outputs
Outputs of similar age
#235,796
of 281,570 outputs
Outputs of similar age from BMC Infectious Diseases
#159
of 168 outputs
Altmetric has tracked 22,879,161 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,691 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,570 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 168 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.